Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
58 GBX | +1.05% | -3.33% | +56.76% |
May. 30 | Afentra seeking further growth opportunities after "milestone" year | AN |
May. 23 | Celadon ships to US; Oxford BioDynamics-Goodbody pact | AN |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 22.89 | 19.09 | 20.85 | 32.02 | 58.09 | 126.3 | 126.3 | - |
Enterprise Value (EV) 1 | 22.89 | -15.98 | -8.694 | 2.133 | 41.77 | 81.42 | 106.8 | 83.9 |
P/E ratio | - | - | - | - | -8.06 x | -39.2 x | 3.51 x | 14.4 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 56.5 x | - | - | - | - | 3.92 x | 1.19 x | 1.4 x |
EV / Revenue | 56.5 x | - | - | - | - | 3.92 x | 1 x | 0.93 x |
EV / EBITDA | -20.1 x | 8.52 x | 6.22 x | -0.57 x | -5.99 x | -12.1 x | 1.7 x | 1.99 x |
EV / FCF | -0.84 x | 8.65 x | 5.48 x | -0.58 x | -7.61 x | -35.4 x | 2.89 x | 7.06 x |
FCF Yield | -120% | 11.6% | 18.3% | -172% | -13.1% | -2.83% | 34.6% | 14.2% |
Price to Book | - | - | - | - | - | 3.33 x | 1.76 x | - |
Nbr of stocks (in thousands) | 220,054 | 220,054 | 220,054 | 220,054 | 220,054 | 220,054 | 220,054 | - |
Reference price 2 | 0.1040 | 0.0868 | 0.0948 | 0.1455 | 0.2640 | 0.5740 | 0.5740 | 0.5740 |
Announcement Date | 3/25/19 | 4/15/20 | 5/27/21 | 4/26/22 | 5/16/23 | 5/30/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 0.4053 | - | - | - | - | 20.76 | 106.5 | 90.02 |
EBITDA 1 | -1.139 | -1.876 | -1.397 | -3.73 | -6.976 | -6.746 | 62.68 | 42.13 |
EBIT 1 | - | - | - | - | -7.171 | 1.858 | 47.85 | 23.6 |
Operating Margin | - | - | - | - | - | 8.95% | 44.92% | 26.22% |
Earnings before Tax (EBT) 1 | - | - | - | - | -7.259 | -0.7126 | 44.11 | 21.68 |
Net income 1 | - | - | - | - | -7.259 | -2.128 | 36.37 | 8.654 |
Net margin | - | - | - | - | - | -10.25% | 34.14% | 9.61% |
EPS 2 | - | - | - | - | -0.0328 | -0.009440 | 0.1633 | 0.0400 |
Free Cash Flow 1 | -27.38 | -1.847 | -1.588 | -3.668 | -5.491 | -3.98 | 36.91 | 11.88 |
FCF margin | -6,755.21% | - | - | - | - | -30.7% | 34.65% | 13.2% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | 58.89% | 28.19% |
FCF Conversion (Net income) | - | - | - | - | - | - | 101.5% | 137.27% |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/25/19 | 4/15/20 | 5/27/21 | 4/26/22 | 5/16/23 | 5/30/24 | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | 14.5 | - | - |
Net Cash position 1 | - | 35.1 | 29.5 | 29.9 | 16.3 | - | 19.5 | 42.4 |
Leverage (Debt/EBITDA) | - | - | - | - | - | 6.365 x | - | - |
Free Cash Flow 1 | -27.4 | -1.85 | -1.59 | -3.67 | -5.49 | -3.98 | 36.9 | 11.9 |
ROE (net income / shareholders' equity) | - | - | - | - | -16.7% | -5.1% | 47.6% | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | - | - | - | - | - | 0.1700 | 0.3300 | - |
Cash Flow per Share 2 | -0.1200 | -0.0100 | -0.0100 | -0.0200 | - | 0.0400 | 0.2500 | 0.1600 |
Capex 1 | - | - | - | - | 0.13 | 1.95 | 10.2 | 18.9 |
Capex / Sales | - | - | - | - | - | 15.06% | 9.56% | 20.97% |
Announcement Date | 3/25/19 | 4/15/20 | 5/27/21 | 4/26/22 | 5/16/23 | 5/30/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+56.76% | 161M | |
+4.86% | 287B | |
+63.46% | 133B | |
-3.77% | 131B | |
-0.21% | 69.66B | |
-0.33% | 53.27B | |
+2.65% | 45.44B | |
-12.40% | 34.29B | |
+23.00% | 34.07B | |
+3.17% | 29.58B |
- Stock Market
- Equities
- SEY Stock
- Financials Afentra plc